Psygen Industries Ltd. Announces Export of LSD to New Zealand and Completion of MDMA Development Program
Calgary, Alberta--(Newsfile Corp. - April 19, 2023) - Psygen Industries Ltd. (together with its subsidiaries, "Psygen") is pleased to announce that its wholly-owned subsidiary, Psygen Labs Inc., completed manufacture of more than 1.5 million microdoses of lysergic acid diethylamide ("LSD"). A portion of the LSD has been exported to New Zealand for use in a ground-breaking Phase II clinical trial sponsored by MindBio Therapeutics ("MindBio"). MindBio's clinical trial will provide Psygen's LSD to participants suffering from major depressive disorder for...
2023-04-19 4:46 PM EDT
Psygen Receives Dealer's Licence from Health Canada
Calgary, Alberta--(Newsfile Corp. - January 17, 2022) - Psygen Industries Ltd. (together with its subsidiaries, "Psygen") is pleased to announce that its wholly-owned subsidiary, Psygen Labs Inc., received a dealer's licence issued by Health Canada on January 17, 2022 (the "Dealer's Licence"). Upon completion of its facility in Calgary, Psygen will begin onsite manufacturing of synthetic psychedelics in accordance with Good Manufacturing Practices ("GMP") for use in clinical and scientific research. Psygen is strongly positioned to manufacture at scale any...
2022-01-17 10:57 AM EST
CORRECTION FROM SOURCE: Psygen Announces use of Psilocybin in Human Trial and Provides Update on IP Portfolio
patent applications filed for manufacturing processespatent-pending technology aims to improve yields and ultimately marginsCalgary, Alberta--(Newsfile Corp. - October 6, 2021) - Psygen Industries Ltd. ("Psygen" or the "Company") provided an update today on use of psilocybin in humans and on its intellectual property portfolio. Psygen is excited to announce that psilocybin recently used in a clinical trial was manufactured by Psygen personnel working with a third-party licensed dealer. The Company is also announcing that Psygen has developed patent-pending technology that...
2021-10-06 7:09 PM EDT
Psygen Announces That Psilocybin from Its Patent-Pending Process Has Been Used in Human Trial
patent applications filed for manufacturing processes patent-pending technology aims to improve yields and ultimately marginsCalgary, Alberta--(Newsfile Corp. - October 6, 2021) - Psygen Industries Ltd. ("Psygen" or the "Company") provided an update today on its intellectual property portfolio and on use of psilocybin in humans. Psygen is excited to announce that psilocybin recently used in a clinical trial was manufactured using Psygen's patent-pending synthetic method. The Company believes that Psygen's patent-pending technology will improve yields and margins on revenue, and that...
2021-10-06 8:00 AM EDT
Psygen Announces Successful Closing of Oversubscribed Convertible Debenture Financing, Sets Value at $30mm
Calgary, Alberta--(Newsfile Corp. - August 5, 2021) - Psygen Industries Ltd. ("Psygen" or the "Company") announced today that it has closed its previously announced non-brokered private placement financing (the "Offering") of unsecured convertible debentures (the "Debentures") for gross proceeds of $5.5 million. The Debentures incur interest of 8.0% per annum. The proceeds will allow Psygen to hire key employees and complete their 17,000 square foot facility, which is anticipated to be the first GMP compliant manufacturing facility...
2021-08-05 8:00 AM EDT
Psygen Industries Ltd. and 1290442 B.C. Ltd. Announce Execution of Definitive Agreement for Reverse Takeover Transaction
Vancouver, British Columbia--(Newsfile Corp. - April 19, 2021) - Further to the press release of Psygen Industries Ltd. ("Psygen") and Larose Ventures Ltd. dated March 24, 2021, Psygen and 1290442 B.C. Ltd. ("1290") are pleased to announce they have entered into an amalgamation agreement (the "Amalgamation Agreement") dated April 16, 2021, pursuant to which Psygen and a newly-formed wholly owned subsidiary of 1290 ("Subco") will amalgamate (such amalgamated entity to be referred to as "Amalco") which will result in a...
2021-04-19 8:00 AM EDT
Psygen Industries Ltd. and Larose Ventures Ltd. Announce Reverse Takeover Transaction of 1290442 B.C. Ltd. by Psygen Industries Ltd. and Brokered Financing Led by Eight Capital and Canaccord
Vancouver, British Columbia--(Newsfile Corp. - March 24, 2021) - Psygen Industries Ltd. ("Psygen") and Larose Ventures Ltd. ("Larose Ventures" or the "Company") are pleased to announce they have entered into a binding letter agreement (the "Letter Agreement") dated March 23, 2021, to complete a business combination by way of a transaction that will constitute a reverse takeover of a wholly-owned subsidiary of the Company, being 1290442 B.C. Ltd. ("SpinCo"), by Psygen (the "Transaction"). The Transaction is conditional on, and will...
2021-03-24 8:00 AM EDT